Apolipoprotein (apo) E and the two B apolipoproteins, apoB48 and apoB100, are important proteins in human lipoprotein metabolism. Commonly occurring polymorphisms in the genes for apoE and apoB result in amino acid substitutions that produce readily detectable phenotypic differences in these proteins. We studied changes in apoE and apoB phenotypes before and after liver transplantation to gain new insights into apolipoprotein physiology. In all 29 patients that we studied, the postoperative serum apoE phenotype of the recipient, as assessed by isoelectric focusing, converted virtually completely to that of the donor, providing evidence that greater than 90% of the apoE in the plasma is synthesized by the liver. In contrast, the cerebrospinal fluid apoE phenotype did not change to the donor's phenotype after liver transplantation, indicating that most of the apoE in CSF cannot be derived from the plasma pool and therefore must be synthesized locally. The apoB100 phenotype (assessed with immunoassays using monoclonal antibody MB19, an antibody that detects a two-allele polymorphism in apoB) invariably converted to the phenotype of the donor. In four normolipidemic patients, we determined the MB19 phenotype of both the apoB100 and apoB48 in the "chylomicron fraction" isolated from plasma 3 h after a fat-rich meal. Interestingly, the apoB100 in the chylomicron fraction invariably had the phenotype of the donor, indicating that the vast majority of the large, triglyceride-rich apoB100-containing lipoproteins that appear in the plasma after a fat-rich meal are actually VLDL of hepatic origin. The MB19 phenotype of the apoB48 in the plasma chylomicron fraction did not change after liver transplantation, indicating that almost all of the apoB48 in plasma chylomicrons is derived from the intestine. These results were consistent with our immunocytochemical studies on intestinal biopsy specimens of organ donors; using apoB-specific monoclonal antibodies, we found evidence for apoB48, but not apoB100, in donor intestinal biopsy specimens.
M F Linton, R Gish, S T Hubl, E Bütler, C Esquivel, W I Bry, J K Boyles, M R Wardell, S G Young
Title and authors | Publication | Year |
---|---|---|
Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer’s disease?
F Vecchio, P Bisceglia, B Imbimbo, M Lozupone, R Latino, E Resta, M Leone, V Solfrizzi, A Greco, A Daniele, M Watling, F Panza, D Seripa |
Therapeutic Advances in Chronic Disease | 2022 |
Insulin Resistance in Peripheral Tissues and the Brain: A Tale of Two Sites
Rhea EM, Banks WA, Raber J |
Biomedicines | 2022 |
APOE mediated neuroinflammation and neurodegeneration in Alzheimer’s Disease
Parhizkar S, Holtzman DM |
Seminars in Immunology | 2022 |
APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer's disease pathology and brain diseases.
Fernández-Calle R, Konings SC, Frontiñán-Rubio J, García-Revilla J, Camprubí-Ferrer L, Svensson M, Martinson I, Boza-Serrano A, Venero JL, Nielsen HM, Gouras GK, Deierborg T |
Molecular Neurodegeneration | 2022 |
APOE4 derived from astrocytes leads to blood-brain barrier impairment.
Jackson RJ, Meltzer JC, Nguyen H, Commins C, Bennett RE, Hudry E, Hyman BT |
Brain : a journal of neurology | 2022 |
Brain integrity is altered by hepatic APOE ε4 in humanized-liver mice.
Giannisis A, Patra K, Edlund AK, Nieto LA, Benedicto-Gras J, Moussaud S, de la Rosa A, Twohig D, Bengtsson T, Fu Y, Bu G, Bial G, Foquet L, Hammarstedt C, Strom S, Kannisto K, Raber J, Ellis E, Nielsen HM |
Molecular Psychiatry | 2022 |
Peripheral apoE4 enhances Alzheimer's pathology and impairs cognition by compromising cerebrovascular function.
Liu CC, Zhao J, Fu Y, Inoue Y, Ren Y, Chen Y, Doss SV, Shue F, Jeevaratnam S, Bastea L, Wang N, Martens YA, Qiao W, Wang M, Zhao N, Jia L, Yamazaki Y, Yamazaki A, Rosenberg CL, Wang Z, Kong D, Li Z, Kuchenbecker LA, Trottier ZA, Felton L, Rogers J, Quicksall ZS, Linares C, Knight J, Chen Y, Kurti A, Kanekiyo T, Fryer JD, Asmann YW, Storz P, Wang X, Peng J, Zhang B, Kim BYS, Bu G |
Nature Neuroscience | 2022 |
Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer's disease.
Giannisis A, Al-Grety A, Carlsson H, Patra K, Twohig D, Sando SB, Lauridsen C, Berge G, Grøntvedt GR, Bråthen G, White LR, Kultima K, Nielsen HM |
Alzheimer's research & therapy | 2022 |
Convergent cerebrospinal fluid proteomes and metabolic ontologies in humans and animal models of Rett syndrome.
Zlatic SA, Duong D, Gadalla KKE, Murage B, Ping L, Shah R, Fink JJ, Khwaja O, Swanson LC, Sahin M, Rayaprolu S, Kumar P, Rangaraju S, Bird A, Tarquinio D, Carpenter R, Cobb S, Faundez V |
iScience | 2022 |
Liver-ing in your head rent free: peripheral ApoE4 drives CNS pathology.
Golden LR, Johnson LA |
Molecular Neurodegeneration | 2022 |
Prophylactic treatment with CN-105 improves functional outcomes in a murine model of closed head injury.
Van Wyck D, Kolls BJ, Wang H, Cantillana V, Maughan M, Laskowitz DT |
Experimental Brain Research | 2022 |
Lipoproteins in the Central Nervous System: From Biology to Pathobiology.
Raulin AC, Martens YA, Bu G |
Annual Review of Biochemistry | 2022 |
ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies.
Raulin AC, Doss SV, Trottier ZA, Ikezu TC, Bu G, Liu CC |
Molecular Neurodegeneration | 2022 |
Exploring the Role of Lipid-Binding Proteins and Oxidative Stress in Neurodegenerative Disorders: A Focus on the Neuroprotective Effects of Nutraceutical Supplementation and Physical Exercise
Scarfò G, Piccarducci R, Daniele S, Franzoni F, Martini C |
Antioxidants | 2022 |
Dalcetrapib and anacetrapib increase apolipoprotein E-containing HDL in rabbits and humans
Brodeur MR, Rhainds D, Charpentier D, Boulé M, Mihalache-Avram T, Mecteau M, Brand G, Pedneault-Gagnon V, Fortier A, Niesor EJ, Rhéaume E, Maugeais C, Tardif JC |
Journal of lipid research | 2022 |
Upstream lipid and metabolic systems are potential causes of Alzheimer's disease, Parkinson's disease and dementias.
Cooper O, Hallett P, Isacson O |
The FEBS journal | 2022 |
The small HDL particle hypothesis of Alzheimer’s disease
Martinez AE, Weissberger G, Kuklenyik Z, He X, Meuret C, Parekh T, Rees JC, Parks BA, Gardner MS, King SM, Collier TS, Harrington MG, Sweeney MD, Wang X, Zlokovic BV, Joe E, Nation DA, Schneider LS, Chui HC, Barr JR, Han SD, Krauss RM, Yassine HN |
Alzheimer's & dementia : the journal of the Alzheimer's Association | 2022 |